IMA950

What is IMA950?

IMA950 is a multi-peptide cancer vaccine made of 11 peptides associated with glioblastoma multiforme, including brevican, CSPG4, FABP7, MET, and BIRC5 peptides plus a hepatitis B virus core antigen peptide. It is intended to stimulate cytotoxic T-lymphocyte and T-helper responses against tumor cells expressing these peptides. It is studied in glioma and related astrocytic and oligodendroglial tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type

Vaccine (Peptide vaccine)

Targets

brevican (BCAN) (antigen), chondroitin sulfate proteoglycan 4 (CSPG4) (antigen), fatty acid binding protein 7, brain (FABP7) (antigen), insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) (antigen), neuroligin 4, X-linked (NLGN4X) (antigen), neuronal cell adhesion molecule (NRCAM) (antigen)

Mechanism

Immune activation, directed at brevican (BCAN), chondroitin sulfate proteoglycan 4 (CSPG4) and fatty acid binding protein 7, brain (FABP7)

Pathways

cytotoxic T-lymphocyte response, T-helper immune response

Therapy area

Oncology

In trials of

CLDX

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Astrocytoma, Grade IIGliomaGlioma, AstrocyticMalignant GliomaOligoastrocytoma, MixedOligodendroglioma

Sources

• NCI Thesaurus

Updated Oct 11, 2026.